



Magnum Compounding LLC  
490 W 84 St, Hialeah, FL 33014  
Phone: (786) 622-2301  
Fax: (786) 622-2319  
Toll Free: (855) 403-6028



## COMPOUNDED INJECTABLE FORMULA INFORMATION SHEET ONLY WITH MEDICAL JUSTIFICATION

**Product Name:** Semaglutide

**Formulation Type:** Sterile Injectable Solution (Subcutaneous Use Only)

**Vial Size:** 2 mL Multi-Dose Vial (MDV)

### ACTIVE INGREDIENTS (per mL)

Ingredients	Strength (mg / mL)	Role & Benefits
Semaglutide	1.2 mg, 2.4 mg, 4.8 mg, 10 mg	GLP-1 receptor agonist for glycemic control and appetite suppression.
Niacinamide	6 mg	Supports insulin sensitivity and reduces inflammation.
L-Carnitine	50 mg	Assists in fatty acid metabolism and energy production.

### OTHER INGREDIENTS:

- Benzyl Alcohol 0.9% (Preservative)
- Water for Injection, USP (Vehicle)
- pH adjusted with Sodium Hydroxide and/or Hydrochloric Acid

**DESCRIPTION:** This compounded formulation combines Semaglutide, a GLP-1 receptor agonist, with Niacinamide and L-Carnitine to support glucose regulation, enhance fat metabolism, and promote metabolic health. It is intended for subcutaneous administration and may be used as part of a comprehensive weight management or metabolic wellness program.

### INDICATIONS:

- Support for weight management and metabolic health
- Adjunct to diet and exercise for glucose regulation
- Fatty acid metabolism and energy enhancement

### DOSAGE & ADMINISTRATION:

- Route: Subcutaneous injection (SC) only
- Typical Dosage: As directed by a licensed healthcare provider
- Administer in the abdomen or thigh using proper aseptic technique

\*This product is to be administered under licensed medical supervision.

**If you have any questions or concerns regarding your medication, please do not hesitate to contact us.**



Magnum Compounding LLC  
490 W 84 St, Hialeah, FL 33014  
Phone: (786) 622-2301  
Fax: (786) 622-2319  
Toll Free: (855) 403-6028

**LET'S DO THIS  
TOGETHER**

**STORAGE:** Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light and heat. Do not freeze.

**WARNINGS & PRECAUTIONS:**

- Do not use in patients with a personal or family history of medullary thyroid carcinoma
- Not for use in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Use caution in patients with renal or hepatic impairment
- Monitor for signs of pancreatitis or hypoglycemia when used with insulin or sulfonylureas

**POTENTIAL SIDE EFFECTS:**

- Localized pain at the injection site
- Mild flushing, tingling, or dizziness
- Rare: allergic reaction or anaphylaxis
- Notify the provider of any unusual or persistent symptoms

**DRUG DISPOSAL:** Unused or expired compounded medications should be disposed of properly according to local regulations. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Consult with your pharmacy or local waste disposal authority for appropriate disposal methods. Magnum Compounding LLC can provide guidance or accept returned compounds for proper disposal when applicable.

**SHIPPING & HANDLING:** Shipped cold. Do not use it if exposed to improper temperature or physical damage. Inspect before use.

**INJECTION SAFETY CONSIDERATIONS (CDC GUIDANCE):**

- Medications should be drawn up in a designated clean medication preparation area using a new sterile syringe and sterile needle.
- Prepare an injection as close as possible to the time of administration to the patient.
- Do NOT leave the needle inserted into a medication vial septum for multiple uses.
- Vials labeled as single-dose or single-use should be used for only a single patient and entered only once.
- Do NOT combine (pool) leftover contents of single-dose or single-use vials or store them for later use.
- If a single-dose or single-use vial has been opened or accessed (e.g., needle-punctured), it should be discarded according to pharmacy policy or at the end of the procedure, whichever is sooner.
- Discard any medication vial if sterility is compromised or questionable.
- Multi-dose vials should be dedicated to a single patient whenever possible.
- Once opened, multi-dose vials must be dated and discarded within 28 days unless otherwise specified by the pharmacy label.

**VISION CHANGES WARNING**

Some patients using medications in the GLP-1 receptor agonist class, including semaglutide, have reported visual changes.

**If you have any questions or concerns regarding your medication, please do not hesitate to contact us.**



Magnum Compounding LLC  
490 W 84 St, Hialeah, FL 33014  
Phone: (786) 622-2301  
Fax: (786) 622-2319  
Toll Free: (855) 403-6028

**LET'S DO THIS  
TOGETHER**

These may include:

- Blurred vision
- Worsening of diabetic retinopathy (primarily in patients with pre-existing diabetes)
- Changes in visual acuity

Patients with a history of diabetic retinopathy or other retinal conditions may be at increased risk.

#### **MONITORING RECOMMENDATION**

Patients are advised to:

- Monitor for any changes in vision during treatment
- Report symptoms such as blurred vision, floaters, or vision loss promptly
- Maintain regular eye examinations, especially if they have diabetes

**CLINICAL CONSIDERATION:** Rapid improvement in blood glucose control may temporarily worsen diabetic retinopathy in some patients. Use of semaglutide should be monitored by a healthcare provider, particularly in patients with a history of retinal disease.

#### **WHEN TO SEEK MEDICAL ATTENTION**

Patients should seek immediate medical attention if they experience:

- Sudden vision loss
- Persistent blurred vision
- Visual disturbances affecting daily activities

**MEDICAL DISCLAIMER:** This information is provided for awareness purposes. Clinical evaluation and monitoring decisions should be determined by the prescribing healthcare provider.

#### **REFERENCE:**

- GLP-1 Receptor Agonists – FDA Prescribing Information
- Niacinamide in Metabolic Health – NIH Database
- L-Carnitine Pharmacological Profile – PubMed/NCBI

**If you have any questions or concerns regarding your medication, please do not hesitate to contact us.**